The paper's citation list
No. | The paper's citation list |
|---|
1 | Editorial - Reflecting on three years of M&TOD - Where we are and where we are going. 2024;4: doi: 10.20517/mtod.2024.65 |
2 | Ultrasonographic fatty liver indicator (US-FLI): a reliable biomarker for non-invasive NAFLD stratification. 2023;3: doi: 10.20517/mtod.2023.21 |
3 | Principles of risk stratification in nonalcoholic fatty liver disease. A narrative review emphasizing non-invasive strategies. 2023;188 doi: 10.37349/edd.2023.00026 |
4 | Endogenous sex hormones and nonalcoholic fatty liver disease in US adults. 2024;44:460 doi: 10.1111/liv.15786 |
5 | Comparison of non-invasive fibrosis scores to predict increased liver stiffness in the general population with unknown liver disease: Searching for the primary physician's best friend. 2022;54:1209 doi: 10.1016/j.dld.2022.03.013 |
6 | Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. 2024;184:375 doi: 10.1001/jamainternmed.2023.8029 |
7 | Validation of five hepatic steatosis algorithms in metabolic‐associated fatty liver disease: A population based study. 2022;37:938 doi: 10.1111/jgh.15799 |
8 | Four hepatic steatosis indices in predicting quantitative computed tomography-based metabolic dysfunction-associated fatty liver disease. 2024;1:62 doi: 10.37349/eemd.2024.00008 |
9 | Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge. 2024;4: doi: 10.20517/mtod.2024.34 |
10 | Mortality risk associated with MASLD, MASLD type and different cardiometabolic risk factors in IBD patients: A long-term prospective cohort study. 2025;57:744 doi: 10.1016/j.dld.2024.11.002 |
